Our Research Methodology
We began with a complete crawl of LumiMeds’ primary website and plan pages to map offerings and pricing. We verified that GLP‑1/GIP plans list three options—the $399 Starter 3‑Month Supply ($133/month), the $649 Value 3‑Month Subscription ($216.33/month), and the $279 Monthly—as well as GLP‑1 plans at $399 per 3 months ($133/month) or $189 monthly. We also documented the site’s prominent “same price for all doses” language and that program summaries include the initial telehealth visit, medication if prescribed, support, and remote monthly check‑ins. (LumiMeds)
Next, we analyzed the Terms of Use, Membership Terms, and Privacy Policy. Key elements include a non‑refundable $60 cancellation fee for most cancellations prior to pharmacy fulfillment, no refunds after shipment, a requirement to give at least 28 days’ notice to stop recurring subscriptions, and arbitration with a 30‑day opt‑out window. Membership Terms state that once a term starts, fees are non‑cancelable and non‑refundable. The Privacy Policy permits sharing personal information with affiliates/partners for marketing under an opt‑in framework. (LumiMeds)
We reviewed treatment content to confirm that the site positions GLP‑1 and GLP‑1/GIP injections as options determined by independent clinicians, and that compounded medications are clearly identified as not FDA‑approved. Select marketing pages indicate the use of a 503B outsourcing facility with fulfillment by a 503A pharmacy for certain plans; the Terms allow clinicians to order labs when appropriate but do not require routine labs for every patient. (LumiMeds)
To evaluate operational experience, we traced the onboarding pathway and confirmed a posted target of approximately 48 hours for provider review. We observed two separate portals (a patient login on the main domain and an app subdomain), which can complicate reorders and message tracking if you switch devices. We confirmed phone and email support channels on the site. (LumiMeds)
Finally, we monitored public feedback and reputation signals during September 2025 and confirmed a mid‑to‑high 4‑star average across ~170+ recent reviews on a major ratings platform, alongside isolated complaints about portal transitions and fulfillment timing. We also verified that on September 9, 2025 the FDA issued a Warning Letter to LumiMeds concerning compounded GLP‑1/GIP claims; we will continue to track the company’s response and any remediation. (Trustpilot)
- Flat-dose pricing with simple tiers; as low as $133/month on multi-month plans.
- Strict refund/cancellation terms including $60 fee pre-fulfillment; no refunds after shipment.
- FDA Warning Letter (Sept 9, 2025) about compounded GLP-1/GIP claims—monitor updates.
